Visual Podcast: Expert Tips For Staving Off De Novo Troubles
This article was originally published in The Gray Sheet
King & Spalding's Quynh Hoang offers device manufacturers a handful of tips for pursuing de novo classification submissions – including urging firms to determine whether clinical studies are needed for a potential de novo submission – in this "Gray Sheet" podcast.
You may also be interested in...
FDA granted more than double the number of de novo petitions in FY 2013 compared to past years, reflecting the availability of the direct de novo pathway recently established by Congress. De novo petitions allow a device that FDA deems to be low-to-moderate risk but without a clear predicate to enter the market without requiring a PMA.
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.